• Skip to main content

Aphios

Inspired by Nature, Enabled by Science®

  • Products
    ▼
    • Enhanced Therapeutic Products Overview
    • Therapeutic Products Pipeline
      ▼
      • Oncology
        ▼
        • Zindol®: Ginger Extract Therapy for CINV
        • APH-0701
        • APH-0911
        • APH-0912
        • APH-0804
        • Taxosomes™
        • Camposomes™
        • Dermos™
        • APH-0201
        • Sperol™
      • Infectious Disease
        ▼
        • APH-0812
        • APH-0202
        • nanoHYP™
        • Asterias™
        • Marinus™
        • HIV/AIDS Therapeutic Vaccine
        • Anti-HIV Therapeutics
        • Anti-Influenza Therapeutics
        • Vaccine Adjuvant Technology
          ▼
          • Anthrax Vaccine Adjuvant
      • CNS Disorders
        ▼
        • APH-1104
        • Xantol™
        • APH-1501: CBD + LDN Nanotherapy for OUD
        • APH-1502: CBD Nanotherapy for CIPNP
        • APH-1503: CBD Nanotherapy for Anxiety Relief
        • APH-1504: CBD Nanotherapy for Multiple Sclerosis
        • APH-1505: CBD Nanotherapy for Epilepsy
        • APH-0802 – nanoTHC™
        • APH-1403
      • Diabetes
        ▼
        • APH-0907
    • Research Chemicals & APIs
      ▼
      • Adhyperforin
      • Adhyperforin DCHA
      • Betulin
      • Betulinic Acid
      • Bryostatin 1
      • Bryostatin 2
      • Bryostatin 3
      • Camptothecin
      • C-ATR
      • Cephalomannine: Anti-Tumor Taxane Compound from Yew Tree
      • Cyclopamine: Steroidal Alkaloid Hedgehog Pathway Inhibitor from Corn Lily
      • Cycloposine: Steroidal Alkaloid from Corn Lily (Veratrum californicum)
      • 10-DAB
      • 9-DHAB
      • Δ9-THC
      • Δ9-THCA
      • Frondoside A
      • 6-Gingerol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • 8-Gingerol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • 10-Gingerol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • Hypericin: Photodynamic Antiviral Compound from St. John’s Wort (Hypericum perforatum)
      • Hyperforin
      • Hyperforin DCHA
      • Jervine: Steroidal Alkaloid Hedgehog Pathway Antagonist from Corn Lily (Veratrum californicum)
      • MLA
      • Muldamine: Steroidal Alkaloid from Corn Lily (Veratrum californicum)
      • Nobiletin: Polymethoxylated Flavone from Citrus Peel (Citrus sinensis)
      • Paclitaxel: Natural Anti-Mitotic Anticancer Compound from Yew (Taxus sp.)
      • Phloridzin Dihydrate: Dihydrochalcone SGLT Inhibitor from Apple Wood (Malus sp.)
      • Sclareolide: Sesquiterpene Lactone from Clary Sage (Salvia sclarea)
      • 6-Shogaol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • Tangeretin: Bioflavonoid from Citrus Peel (Citrus sinensis)
      • Veratramine: Steroidal Alkaloid from Corn Lily (Veratrum californicum)
    • Equipment
    • Quality of Life Medicines
  • Technology
    ▼
    • Enabling Technology Platforms
    • Drug Discovery
    • Drug Manufacturing
    • Drug Delivery
      ▼
      • CFN
      • PNS
      • PNP
    • Drug Safety
      ▼
      • CFI™ Mechanisms of Action & Applications
    • Microbial Cell Disruption
    • Crystallization
      ▼
      • Natural Therapeutics Crystallization – CRY
      • SuperFluids Crystallization Process
    • Biomass Pretreatment
      ▼
      • Cellulosic Biomass Pretreatment (CBP) – Aosic Platform
  • Investors
    ▼
    • Investors Overview
      ▼
      • Aphios Pharma LLC
      • Aphios International LLC
      • Zindol LLC
  • About
    ▼
    • Company Overview
    • Management
    • Directors
    • Scientific Advisors
    • Community Involvement
    • Press Releases
    • Events
    • Careers
  • Contact
  • Shop
  • Products
    • Enhanced Therapeutic Products Overview
    • Therapeutic Products Pipeline
      • Oncology
        • Zindol®: Ginger Extract Therapy for CINV
        • APH-0701
        • APH-0911
        • APH-0912
        • APH-0804
        • Taxosomes™
        • Camposomes™
        • Dermos™
        • APH-0201
        • Sperol™
      • Infectious Disease
        • APH-0812
        • APH-0202
        • nanoHYP™
        • Asterias™
        • Marinus™
        • HIV/AIDS Therapeutic Vaccine
        • Anti-HIV Therapeutics
        • Anti-Influenza Therapeutics
        • Vaccine Adjuvant Technology
          • Anthrax Vaccine Adjuvant
      • CNS Disorders
        • APH-1104
        • Xantol™
        • APH-1501: CBD + LDN Nanotherapy for OUD
        • APH-1502: CBD Nanotherapy for CIPNP
        • APH-1503: CBD Nanotherapy for Anxiety Relief
        • APH-1504: CBD Nanotherapy for Multiple Sclerosis
        • APH-1505: CBD Nanotherapy for Epilepsy
        • APH-0802 – nanoTHC™
        • APH-1403
      • Diabetes
        • APH-0907
    • Research Chemicals & APIs
      • Adhyperforin
      • Adhyperforin DCHA
      • Betulin
      • Betulinic Acid
      • Bryostatin 1
      • Bryostatin 2
      • Bryostatin 3
      • Camptothecin
      • C-ATR
      • Cephalomannine: Anti-Tumor Taxane Compound from Yew Tree
      • Cyclopamine: Steroidal Alkaloid Hedgehog Pathway Inhibitor from Corn Lily
      • Cycloposine: Steroidal Alkaloid from Corn Lily (Veratrum californicum)
      • 10-DAB
      • 9-DHAB
      • Δ9-THC
      • Δ9-THCA
      • Frondoside A
      • 6-Gingerol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • 8-Gingerol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • 10-Gingerol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • Hypericin: Photodynamic Antiviral Compound from St. John’s Wort (Hypericum perforatum)
      • Hyperforin
      • Hyperforin DCHA
      • Jervine: Steroidal Alkaloid Hedgehog Pathway Antagonist from Corn Lily (Veratrum californicum)
      • MLA
      • Muldamine: Steroidal Alkaloid from Corn Lily (Veratrum californicum)
      • Nobiletin: Polymethoxylated Flavone from Citrus Peel (Citrus sinensis)
      • Paclitaxel: Natural Anti-Mitotic Anticancer Compound from Yew (Taxus sp.)
      • Phloridzin Dihydrate: Dihydrochalcone SGLT Inhibitor from Apple Wood (Malus sp.)
      • Sclareolide: Sesquiterpene Lactone from Clary Sage (Salvia sclarea)
      • 6-Shogaol: Bioactive Compound from Ginger Root (Zingiber officinale)
      • Tangeretin: Bioflavonoid from Citrus Peel (Citrus sinensis)
      • Veratramine: Steroidal Alkaloid from Corn Lily (Veratrum californicum)
    • Equipment
    • Quality of Life Medicines
  • Technology
    • Enabling Technology Platforms
    • Drug Discovery
    • Drug Manufacturing
    • Drug Delivery
      • CFN
      • PNS
      • PNP
    • Drug Safety
      • CFI™ Mechanisms of Action & Applications
    • Microbial Cell Disruption
    • Crystallization
      • Natural Therapeutics Crystallization – CRY
      • SuperFluids Crystallization Process
    • Biomass Pretreatment
      • Cellulosic Biomass Pretreatment (CBP) – Aosic Platform
  • Investors
    • Investors Overview
      • Aphios Pharma LLC
      • Aphios International LLC
      • Zindol LLC
  • About
    • Company Overview
    • Management
    • Directors
    • Scientific Advisors
    • Community Involvement
    • Press Releases
    • Events
    • Careers
  • Contact
  • Shop

Press Releases

← Back to Press Releases

Life Science Investments Interview Aphios’ CEO Dr. Trevor P. Castor on The New Era of Life Sciences 2026

The New Era of Life Sciences 2026

Interview transcript:

Dr. Trevor P. Castor, President & CEO, Aphios Corporation

You’ve recently received a U.S. patent for room-temperature mRNA vaccines. What is the promise of this innovation?

The innovation is based on double nano-encapsulation of mRNA vaccines. Traditionally, mRNA is encapsulated in lipid nanoparticles to enable transfer into cells, but lipids are inherently unstable. What we have done is take an mRNA lipid nanoparticle and further encapsulate it within biodegradable polymer nanoparticles. These polymers are significantly more stable at room temperature and act as a protective matrix for the lipid nanoparticles, enhancing overall stability while also enabling sustained release.

This sustained release increases exposure of dendritic and other immune cells to the mRNA over days or weeks rather than minutes or hours. As a result, patients can mount a stronger and more durable immune response, potentially reducing the need for frequent booster shots. The next steps involve conducting clinical trials to demonstrate extended release and room-temperature stability, followed by the FDA approval process.

So the science behind this innovation translates into other disease areas?

Yes, absolutely. While COVID remains relevant, mRNA is a platform technology with applications far beyond infectious disease. The same principles can be applied to areas such as Alzheimer’s disease, cancer, rare disorders, and other chronic conditions.

The room-temperature stability and extended-release features are broadly applicable across these indications. What we have achieved with COVID is highly translatable to other diseases where controlled delivery and sustained exposure are critical.

Stepping back to Aphios’ drug-delivery technology more broadly, what is the one thing you can do that larger companies currently cannot?

Our key differentiator is the use of solvent-free technologies to manufacture nanoparticles. Instead of organic solvents like methylene chloride or ethyl acetate, we use supercritical fluids such as carbon dioxide or nitrous oxide, which exhibit enhanced thermodynamic properties when compressed.

This single-step, scalable process allows us to nano-encapsulate active ingredients efficiently. For example, we are developing cannabinoid nanoparticles for indications such as pain, epilepsy, multiple sclerosis, anxiety, and opiate addiction. The same technology is also used for double nano-encapsulation of mRNA, making it highly versatile.

You’ve mentioned Alzheimer’s disease as a key application. How does your technology help address the challenge of treating the disease?

The fundamental challenge is transporting molecules from the bloodstream into the brain due to the blood–brain barrier. Nanoparticles facilitate transport across this barrier, allowing us to target specific receptors or proteins involved in Alzheimer’s disease.

We are pursuing two approaches. One involves upregulating alpha secretase to reduce amyloid plaques and promote synaptogenesis, potentially allowing not only disease arrest but recovery. The other targets the CCR5 gene, associated with aging, inflammation, and Alzheimer’s. We have demonstrated delivery into the hippocampus and are exploring intranasal administration to avoid systemic exposure and reduce first-pass metabolism in the liver.

You touched on toxicity reduction using nanoparticles. Can you elaborate on that benefit?

Nanoparticles have been shown to significantly reduce toxicity for several compounds. For example, amphotericin B, used in fungal infections, had its toxicity reduced by a factor of 32 when delivered via nanoparticles, enabling intravenous use.

Similar reductions in toxicity have been demonstrated for doxorubicin and other anticancer drugs. This principle underpins much of our work, particularly in targeting sensitive organs like the brain while minimizing systemic side effects.

You’ve also received an NIH grant for treating chemotherapy-induced nausea. Can you tell us about that program and what makes it unique?

The product is called Zindol, designed to treat chemotherapy-induced nausea and vomiting. Quality of life is critical for cancer patients, and nausea can prevent patients from continuing treatment. Zindol has shown strong efficacy in preventing these symptoms.

We previously completed a large, randomized, multi-center, placebo-controlled clinical trial involving 644 cancer patients. The results showed strong efficacy, no side effects, and low cost. Zindol is derived from ginger, with active ingredients isolated and formulated into a highly standardized and bioavailable capsule.

The NIH grant supports this work, allowing us to refine the formulation and advance the product through the next clinical phase.

What types of partnerships are you actively seeking over the next year?

We are seeking collaborative partners for several programs. These include a pivotal Phase 3 trial for Zindol, a phase 2 trial for Alzheimer’s disease, and partnerships around our nanoparticle platform for extended-release therapeutics.

We are particularly interested in applications such as GLP-1 agonists. We have demonstrated oral bioavailability for insulin peptides using our SFS-PNS technology, and we believe this approach could be effective and cost-efficient for GLP-1 therapies as well.

Looking ahead, what would success look like one year from now in a best-case scenario?

In the best-case scenario, we would complete a crossover financing round for Aphios Corporation and its subsidiaries. As a platform company, we have created several special-purpose vehicles for different indications, including Zindol, cannabinoids, and Alzheimer’s disease.

Our goal is to raise crossover funding to advance Zindol and prepare for an IPO by year-end. That capital would allow us to move multiple assets forward and position the company for its next phase of growth.

Finally, you mentioned botanical drugs. How do you see this area evolving?

We see significant momentum building around botanical and natural-product-based therapeutics. With increased focus on these products, we believe the field will continue to expand rapidly.

This aligns closely with what we have been doing at Aphios, and we are well positioned to benefit from that broader shift toward natural and botanical drug development.

 

Aphios

Inspired by Nature, Enabled by Science®

© 2026 Aphios Corporation

Contact Us

  • [email protected]
  • (781) 932-6933
  • 87 Main Street, North Reading, MA 01864 USA
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram
  • Tik Tok